Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -2.68%33 3-Year EPS without NRI Growth Rate is 50.90% as of Jun. 2026, which is 237% above its 10-year median of 15.10. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 656 Medical Devices & Instruments companies, Standard BioTools ranks better than 88.87% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 50.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 12.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 12.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Standard BioTools was 63.60% per year. The lowest was -66.50% per year. And the median was 15.10% per year.
Standard BioTools (NAS:LAB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Standard BioTools 3-Year EPS without NRI Growth Rate Related Terms
LAB vs CV, ELMD, CATX: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Standard BioTools's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Standard BioTools's 3-Year EPS without NRI Growth Rate falls into.
Standard BioTools 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 50.90% mean?
Standard BioTools (LAB) has a 3-Year EPS without NRI Growth Rate of 50.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Standard BioTools and its competitors. This is 237% above median its historical median of 15.10. According to the industry distribution chart, Standard BioTools ranks #73 out of 656 companies in the Medical Devices & Instruments industry, placing it in the top 11.1%.
Is Standard BioTools' 3-Year EPS without NRI Growth Rate too high?
Standard BioTools' current 3-Year EPS without NRI Growth Rate of 50.90% is 237% above median its 10-year median of 15.10. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Standard BioTools' value of 50.90% is 532.3% above this industry median. Based on the distribution chart, Standard BioTools ranks #73 out of 656 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' 3-Year EPS without NRI Growth Rate compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #73 out of 656 companies for 3-Year EPS without NRI Growth Rate. This places Standard BioTools in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Standard BioTools' value of 50.90% is 532.3% above this benchmark. While the company's 10-year median is 15.10 vs. the industry median of 8.05, Standard BioTools has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current 3-Year EPS without NRI Growth Rate of 50.90% is 532.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current 3-Year EPS without NRI Growth Rate is 50.90%, which is 237% above median its own 10-year median of 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 7.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 50.90%, which is 237% above median its 10-year median of 15.10 and 532.3% above the Medical Devices & Instruments industry median of 8.05. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Standard BioTools (LAB), the current 3-Year EPS without NRI Growth Rate is 50.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 7.9% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Fairly Valued.
Key valuation signals for LAB:
3-Year EPS without NRI Growth Rate: 50.90% (237% above median its 10-year median of 15.10)
GF Value™: $0.71 vs. price of $0.65 (7.9% below fair value)
Industry Position: 532.3% above the Medical Devices & Instruments median (#73 of 656)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
